Cancer Family
Malignant Mesothelioma
CI-CAN-00000240Explore in graph →
Top-level96 active trials4 approved drugs11 evidence items
- NCIt
- C4456
- ICD-10
- C45
- DOID
- 1790
- MeSH
- D000086002
- MeSH
- D008654
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000240Explore in graph →
Clinical trials
478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (81)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion(MpeTK01) | completed | Phase 1 | 19 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 |
| Aug 1, 2023 |
| clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT02798536 | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | completed | Phase 1 | 210 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02838745 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM | terminated | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04481672 | Intravenous Magnesium in Patients Receiving Cisplatin | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02049060 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | completed | Phase 1 / Phase 2 | 31 | Armando Santoro, MDOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01503177 | Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 | 15 | Mayo ClinicOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT00535951 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Raphael Bueno, MDOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01675765 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | completed | Phase 1 | 60 | Aduro Biotech, Inc.INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT02151448 | αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies | completed | Phase 1 / Phase 2 | 64 | David BartlettOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01119664 | Combination Gene Transfer and Chemotherapy | completed | Phase 1 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03436732 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01445392 | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2018 | clinicaltrials |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01355965 | Autologous Redirected RNA Meso-CIR T Cells | completed | Phase 1 | 18 | University of PennsylvaniaOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01134146 | Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) | completed | Phase 1 / Phase 2 | 12 | Virttu Biologics LimitedINDUSTRY | 1 | Jun 9, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2023source: clinicaltrials